Researchers with Pfizer and IBM developed an artificial intelligence (AI) model that they claim can predict the eventual onset of Alzheimer’s disease with 71% accuracy based on a language sample.

Investigators at the Case Western Reserve University School of Medicine identified a previously unknown gene and the resultant protein that may potentially slow the progress of Alzheimer’s disease.

Roche Holding and partner AC Immune called a halt to two late-stage studies of the companies’ crenezumab drug for early Alzheimer’s, the latest in a string of failures to find a treatment for the progressive brain disease.